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Abstract
Background: Anterior uveitis is the most common extra-articular manifestation of ankylosing spondylitis (AS).
AS-related anterior uveitis frequently presents as acute, recurrent iridocyclitis; therefore, AS is often initially
suspected by an ophthalmologist, not by a rheumatologist. In this study, we aimed to investigate the
relationship between the recurrence of anterior uveitis and the subsequent incidence of AS.
Methods: From a national sample cohort, 10,483 patients with new-onset uveitis between 2004 and 2013 and
52415 matched control subjects who had never experienced uveitis were selected. Among the patients with new-
onset uveitis, a subpopulation of patients with recurrent uveitis, defined as a minimum 120-day reported interval
between consecutive claims of uveitis (based on diagnostic codes) treated with local or systemic steroids or
immune-modulating drugs, was identified. The incidence rates of AS were calculated according to the number of
episodes of uveitis, and the incidence rate ratios (IRRs) were derived on the basis of the incidence rate in the
control group.
Results: The incidence rate per 100,000 person-years of AS after the first uveitis episode was 121.5, whereas the
incidence in the control group was 16.9 (IRR, 7.40; 95% CI, 4.99–10.98); after the second uveitis episode, the IRR
increased to 17.71 (95% CI, 10.44–30.06). In male and female patients with recurrent uveitis, the incidence rates of
AS were 284.1 and 268.7 per 100,000 person-years, respectively. In patients aged under 40 years, the IRR of the
recurrent uveitis group was 46.78 (95% CI, 19.61–111.61). In patients aged over 59 years, AS incidence in the
recurrent uveitis group did not differ from that in the control group.
Conclusions: The risk of subsequent AS increased with the number of episodes of anterior uveitis. This quantitative
evidence could contribute to the establishment of a rationale for ancillary workup for possible systemic associations
in patients with recurrent uveitis.
Keywords: Ankylosing spondylitis, Uveitis, Recurrence, Incidence rate
Background
Uveitis is one of the important clinical signs of systemic
inflammatory diseases. Identification of systemic associa-
tions in patients with uveitis is important not only to de-
termine the etiology of ocular inflammation and
improve visual prognosis but also to improve the out-
come of the systemic conditions themselves through a
targeted therapeutic approach. Bilateral occurrence,
granulomatous appearance, or recurrence of anterior
uveitis, or posterior extension/involvement of uveitis,
might be a clue to a possible systemic association, and
ancillary tests should be considered in such cases [1].
Ankylosing spondylitis (AS) is a chronic inflammatory
disease with axial spondyloarthritis whose classification
criteria include the presence of anterior uveitis [2]. A re-
cent meta-analysis demonstrated that anterior uveitis
was the most common extra-articular manifestation of
AS, with a prevalence of 25.8% [3]. A rough quantitative
estimate of the association between anterior uveitis and
the subsequent risk of AS can be obtained from previous
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studies. For example, researchers in a previous study
found that the prevalence of AS in the general population
varied from < 0.01% to 1.8% globally [4], whereas other
studies have shown that AS was prevalent in 4.7–9.3% of
patients with anterior uveitis visiting uveitis referral cen-
ters [5, 6]. However, these results do not provide quantita-
tive information regarding the risk of subsequent AS in
patients with uveitis in the general population.
Therefore, in this study, we investigated the relationship
between the recurrence of uveitis and the incidence of
subsequent AS in the Korean population by using data
from a 12-year national sample cohort. Furthermore, we
provide partial quantitative evidence regarding additional
workup, including laboratory tests and radiographic
imaging, in patients with recurrent anterior uveitis.
Methods
Source population
The present study was exempt from ethical review by
the institutional review board because the data origi-
nated from de-identified secondary data released by the
National Health Insurance Service (NHIS) for research
purposes. The NHIS is a compulsory national health in-
surance that provides universal coverage for almost all
residents in Korea. For reimbursement, all healthcare
providers submit insurance claims to the NHIS with
data including information on demographics, diagnostic
codes, prescription records, and healthcare facilities.
Therefore, these data have a centralized database struc-
ture. The dataset used in this study is an NHIS national
sample cohort comprising claims submitted by health-
care providers from 2002 through 2013. The total popu-
lation of this cohort consisted of 1,025,340 nationally
representative random subjects, which represents ap-
proximately 2.2% of the total number of patients en-
rolled in NHIS in 2002. Patients were selected using the
stratified random sampling method with 1476 strata
according to sex, age, and income level [7].
Study variables
We identified cases of anterior uveitis by identifying
specific International Classification of Diseases, Tenth
Revision (ICD-10), diagnostic codes (ICD-10 codes H20,
H20.0, H20.00, H20.01, H20.04, H20.09, H20.1, H20.8,
and H20.9) between January 1, 2002, and December 31,
2013. To specifically include cases of anterior uveitis, we
selected patients who were treated using steroids or im-
munosuppressive agents (Additional file 1: Table S1) on
the same day they were diagnosed with a diagnostic code
of anterior uveitis. We washed out the first 2 years
(2002–2003) for newly detected cases. Among patients
diagnosed with AS, those who were diagnosed with an-
terior uveitis after their AS diagnosis, based on the visit-
ation date, were excluded. Identification of patients with
AS using this procedure was based on any claim with a
diagnostic code of AS (ICD-10 codes M45.0–45.9).
Ultimately, 10,483 patients with incident anterior uveitis
in the years 2004–2013 were selected as the study group.
The day of the initial diagnosis of uveitis, with treat-
ment, was designated as the index date of the first uve-
itis episode. We matched up to five control subjects
without uveitis from the population cohort to every pa-
tient with uveitis according to age, sex, household in-
come level, and the year of uveitis diagnosis. The first
day of the year used to match patients with uveitis and
control subjects was designated as the index date for the
control patients.
According to the Standardization of Uveitis
Nomenclature Working Group [8], the term recurrent
uveitis describes episodes of uveitis separated by at
least 3 months of inactivity without treatment. With
this claim-based dataset, information about uveitis ac-
tivity could not be retrieved, and we assumed that
uveitis with a prescription of steroid or immunosup-
pressive agent was active. Details of the prescription
provided the duration for which systemic medications,
such as oral medication or injection, were supposed
to be administered. However, we could not determine
the duration for which topical medications, such as
steroid ophthalmic solutions, were applied by the pa-
tients based on the prescription data. Considering
that a bottle of topical steroid is usually used within
1 month, we defined uveitis recurrence as claims of
anterior uveitis with treatment separated by at least
120 days. In the uveitis group, patients who experi-
enced recurrence at least once were designated as the
recurrent uveitis group and the day of first recurrence
was designated as the index date for the second uve-
itis episode (Fig. 1).
Subsequent AS cases were operationally defined as
those involving patients with diagnostic codes of AS
(ICD-10 codes M45.0–45.9) claimed at a general hospital
or referral center. Any patients who had also been diag-
nosed with systemic lupus erythematosus (ICD-10 code
M32.0) or rheumatoid arthritis (RA; ICD-10 code M05.0
or M06.0) were excluded. Patients diagnosed with AS
before 2004 were also excluded to ensure that the AS
group included only patients with new episodes. The day
of the first visit for AS was designated as the index date.
A brief data exploration was conducted to obtain the
overall prevalence and sex-specific distribution of AS to
confirm the validity of the operational definition.
Detailed information of the patients is available in
Additional file 2: Table S2.
To aid in the interpretation of the results of this study,
we performed an additional analysis with disease con-
trols; patients with RA (ICD-10 codes M05.0–05.9,
M06.0–06.9) and herniated intervertebral disc (HIVD;
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ICD-10 code M51.2) were included as the disease con-
trol subjects. The above-mentioned analysis regarding
AS was repeated for RA and HIVD.
Statistical analysis
The primary outcome of this study was the incidence
rate ratio (IRR) of AS according to the number of epi-
sodes of uveitis: control group (no uveitis), “all uveitis”
group (at least one uveitis episode), and recurrent uveitis
group (at least two uveitis episodes). The time period
was tracked from the index date of each group to (1) the
day of AS diagnosis, if any; (2) the day of death, if any;
or (3) the last day of the cohort analysis. Incidence rates
were calculated as the number of people in whom AS
developed after each uveitis episode divided by the total
person-time at risk during the study period. The IRR
and its 95% CI for AS were calculated using Poisson re-
gression models (i.e., generalized linear models with a
Poisson log-linear link function and person-years as the
offset variable) based on the incidence rate of AS in the
control group. Potential confounding variables such as
age, sex, level of income, and year at diagnosis of uveitis
episode were included in this model. Separate subgroup
analyses with sex and age were performed. Age was
stratified into three subgroups: < 40, 40–59, and > 59
years. Statistical analyses were performed using SAS
software version 9.3 (SAS Inc., Cary, NC, USA) and R
version 3.3.2 (R Foundation for Statistical Computing,
Vienna, Austria; http://www.r-project.org). The cutoff
for statistical significance was set at P < 0.05.
Results
In the present study, 10,483 patients with newly devel-
oped anterior uveitis were identified during the period
2004–2013; the average incidence of anterior uveitis was
102.2 per 100,000 person-years. The male/female ratio
was 1.14. Table 1 shows the baseline sociodemographic
composition of the study population for the three
groups: the control group, the “all uveitis” group, and
the recurrent uveitis group. We examined 10,483 pa-
tients with uveitis and 52,415 sociodemographically
matched control subjects. Among the 10,483 patients
with uveitis, 2050 (19.6%) experienced at least one or
more episodes of uveitis. Excluding the 12 patients who
were diagnosed with AS before the second uveitis epi-
sode, the recurrent uveitis group comprised 2038 pa-
tients. AS developed in 0.08% of the control group
subjects, in 0.54% of the patients in the “all uveitis”
group, and in 1.03% of those in the recurrent uveitis
group (P < 0.001). Age, sex, household income, and year
of the index date were similar between the control group
and uveitis group because these variables were used for
matched sampling. The year of the index date in the re-
current uveitis group was later than that in the “all uve-
itis” group, because the first attacks preceded the
second. The median age of the recurrent uveitis group
was less than that of the “all uveitis” group (47.5 years vs
52.5 years). For patients with at least one episode of uve-
itis, the median number of uveitis episodes before AS
development was 2 (IQR, 1–3), and the median interval
between the first episode of uveitis and AS development
was 103.3 weeks (interquartile range, 22.6–214.7 weeks).
Incidence rates per 100,000 person-years of AS in pa-
tients in the “all uveitis” group, recurrent uveitis group,
and control group are shown in Fig. 2. The IRRs corre-
sponding to each condition are summarized in Table 2.
The incidence rate per 100,000 person-years of AS was
16.9 (95% CI, 12.3–22.7) in the control group. Among
patients who experienced a uveitis episode at least once,
the AS incidence rate increased to 121.5/100,000
Fig. 1 Flowchart depicting the classification of patients into the “all uveitis,” recurrent uveitis, and control groups. NHIS-NSC National Health
Insurance Service - National Selection Cohort
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Table 1 Baseline demographics of patients with uveitis and matched control subjects
Control subjects (n = 52,415) All uveitis (n = 10,483) Recurrent uveitis (n = 2038) P value
Ankylosing spondylitis < 0.001
No 52,371 (99.9%) 10,426 (99.5%) 2017 (99.0%)
Yes 44 (0.08%) 57 (0.54%) 21 (1.03%)
Sex 0.983
Male 28,015 (53.4%) 5603 (53.4%) 1085 (53.2%)
Female 24,400 (46.6%) 4880 (46.6%) 953 (46.8%)
Age at diagnosis (years) < 0.001
< 30 9030 (17.2%) 1806 (17.2%) 267 (13.1%)
30–39 7535 (14.4%) 1507 (14.4%) 360 (17.7%)
40–49 8980 (17.1%) 1796 (17.1%) 406 (19.9%)
50–59 8030 (15.3%) 1606 (15.3%) 350 (17.2%)
60–69 8380 (16.0%) 1676 (16.0%) 322 (15.8%)
≥ 70 10,460 (20.0%) 2092 (20.0%) 333 (16.3%)
Household income > 0.999
First quintile 8760 (16.7%) 1752 (16.7%) 350 (17.2%)
Second quintile 7510 (14.3%) 1502 (14.3%) 295 (14.5%)
Third quintile 9650 (18.4%) 1930 (18.4%) 369 (18.1%)
Fourth quintile 11,200 (21.4%) 2240 (21.4%) 437 (21.4%)
Fifth quintile (high) 15,295 (29.2%) 3059 (29.2%) 587 (28.8%)
Year of diagnosis < 0.001
2004–2005 9020 (17.2%) 1804 (17.2%) 156 (7.67%)
2006–2007 8980 (17.1%) 1796 (17.1%) 313 (15.4%)
2008–2009 9920 (18.9%) 1984 (18.9%) 390 (19.2%)
2010–2011 12,440 (23.7%) 2488 (23.7%) 559 (27.5%)
2012–2013 12,055 (23.0%) 2411 (23.0%) 617 (30.3%)
Fig. 2 Incidence of ankylosing spondylitis, rheumatoid arthritis, and herniated intervertebral disc according to uveitis episode numbers
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person-years (95% CI, 92.0–157.4). The incidence rates
rose to 277.3 (95% CI, 171.6–423.8) in patients who ex-
perienced more than two episodes of uveitis. As disease
controls, the RA and HIVD incidences did not show a
correlation with the occurrence or recurrence of uveitis.
Subgroup analysis for age and sex are provided in
Table 3 and Fig. 3. Among the controls, AS occurred
predominantly in males (20.4 vs 12.7 per 100,000
person-years). However, among patients with recurrent
uveitis, the predilection for male sex was not prominent
(284.1 vs 268.7 per 100,000 person-years). In patients
aged under 40 years, the IRR for the recurrent uveitis
group was 46.78 (95% CI, 19.61–111.61). In contrast, AS
incidence in the recurrent uveitis groups aged over 59
years did not differ from that of the controls.
Discussion
In this retrospective, community-based cohort study, we
observed that the incidence rate of AS increased with re-
currence of episodes of uveitis: 7.4-fold after one uveitis
episode and 17.7-fold after two episodes. Furthermore,
age and sex had an impact on the association between
the number of uveitis episodes and subsequent AS inci-
dence among the groups.
The methodology used for detecting the recurrence of
episodes of uveitis is the main highlight of the present
study. We had to identify whether a patient with uveitis
had a 90-day inactive phase without uveitis treatment
during sequential visits with a diagnostic code of uveitis.
Considering that claims with a uveitis diagnostic code
could not guarantee an active episode, claims with
Table 2 Incidence rate ratio of diseases, along with number of episodes of uveitis
Disease Group No. of diseases Person-years IR IRR (95% CI) P value
AS Control subjects 44 52,415 16.9 1 (reference)
All uveitis 57 10,483 121.5 7.40 (4.99–10.98) < 0.001
Recurrent uveitis 21 2038 277.3 17.71 (10.44–30.06) < 0.001
RA Control subjects 141 52,241 54.5 1 (reference)
All uveitis 30 10,439 64.0 1.16 (0.78–1.71) 0.473
Recurrent uveitis 6 2038 78.6 1.45 (0.64–3.28) 0.377
HIVD Control subjects 671 51,833 262.2 1 (reference)
All uveitis 117 10,329 252.9 0.97 (0.80–1.18) 0.757
Recurrent uveitis 18 2019 238.4 0.93 (0.58–1.48) 0.750
Abbreviations: AS Ankylosing spondylitis, HIVD Herniated intervertebral disc, IR Incidence rate per 100,000 person-years, IRR Incidence rate ratio,
RA Rheumatoid arthritis
Table 3 Incidence rate ratio of diseases along with sex and number of episodes of uveitis
Subgroup Group No. of AS Person-years IR IRR (95% CI) P value
By age
< 40 years Control subjects 11 86,359 12.7 1 (reference)
All uveitis 32 15,430 207.4 17.64 (8.87–35.09) < 0.001
Recurrent uveitis 12 2461 487.5 46.78 (19.61–111.61) < 0.001
40–59 years Control subjects 16 87,723 18.2 1 (reference)
All uveitis 19 15,745 120.7 6.70 (3.44–13.06) < 0.001
Recurrent uveitis 8 2994 267.2 15.12 (6.41–35.65) < 0.001
> 59 years Control subjects 17 85,785 19.8 1 (reference)
All uveitis 6 15,739 38.1 1.90 (0.75–4.81) 0.178
Recurrent uveitis 1 2119 47.2 2.46 (0.33–18.53) 0.382
By sex
Male Control subjects 29 142,124 20.4 1 (reference)
All uveitis 33 25,678 128.5 6.34 (3.84–10.44) < 0.001
Recurrent uveitis 12 4224 284.1 14.38 (7.28–28.41) < 0.001
Female Control subjects 15 117,744 12.7 1 (reference)
All uveitis 24 21,235 113.0 9.54 (4.99–18.24) < 0.001
Recurrent uveitis 9 3350 268.7 23.61 (10.05–55.47) < 0.001
Abbreviations: AS Ankylosing spondylitis, IR Incidence rate per 100,000 person-years, IRR Incidence rate ratio
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corresponding diagnostic codes and a prescription code
for either steroid or immunosuppressive agents on the
same day as the diagnosis were designated active uveitis
cases. Thereafter, we defined recurrence of uveitis as
cases where the time interval between two episodes of
active anterior uveitis was more than 120 days, assuming
that a bottle of topical steroid is usually used for 1
month. However, it was possible that the actual duration
of application of ophthalmic solutions was less than 1
month, and our criterion of 120 days for defining uveitis
recurrence was too long. To confirm whether our study
results based on this criterion were stable and robust,
we recalculated the primary outcome of the study with
different values for time of recurrence interval and
found that the results did not vary substantially
(Additional file 3: Table S3). Thus, although the criterion
for the time interval between claims for identifying recur-
rence was not indisputably definite, this was estimated to
have no significant impact on the results of this study.
We performed additional analyses with disease con-
trols to support the methodology used in this study be-
cause the results of a claim-based cohort study could
potentially be biased by the increasing annual use of
healthcare, especially in chronic diseases, or by the avail-
ability of healthcare for only certain diseases. RA is
known to be a prevalent inflammatory arthritis that is
not associated with uveitis [9]. In our study, RA did not
show a correlation with uveitis, either as a single episode
or recurrent. HIVD is a representative spondylopathy
that is presumably not related to uveitis. If a patient with
uveitis had a symptom of spondylopathy and thus the
possibility of the patient visiting a spine clinic, the HIVD
detection rate hence would have been higher. However,
the detected occurrence of HIVD among patients with
uveitis was not different from that in the control sub-
jects. On the basis of these results, we assumed that our
method of assessing the risk of systemic association in
patients with uveitis was not significantly biased.
Male predominance is a well-known characteristic of
AS. However, it was not prominent in patients with re-
current uveitis. Therefore, in managing female patients
with recurrent uveitis, the possibility of the AS associ-
ation should not be underestimated. The age-specific
subgroup analysis showed that recurrent uveitis was as-
sociated with a substantially elevated risk of AS develop-
ment in younger patients, and additional workup for
uveitis should be considered to investigate any systemic
association, including AS.
Although a claim data-based epidemiological analysis
is advantageous for studying a rare disease and its asso-
ciations with other diseases, there are certain limitations.
First, the diagnoses of uveitis and AS were not clinically
confirmed individually according to strict classification
criteria, and overestimation or underestimation of the
presence of diseases could have occurred. To restrict the
overestimation of incident cases, we added the precondi-
tion that the identification of a uveitis episode required
the simultaneous prescription of a local or systemic ster-
oid or immunosuppressive agent and excluded patients
with AS who had diagnostic codes of systemic lupus ery-
thematosus or RA. Underestimation was also possible if
a patient with a certain disease did not use the NHIS. In
addition, systemic treatment for anterior uveitis might
suppress or mask the incidence of subsequent AS. How-
ever, because anterior uveitis can usually be managed
with topical and oral steroid administration for a limited
period, it is unlikely that this treatment can suppress the
onset of subsequent AS itself. Second, some potentially
useful information was unavailable because medical re-
cords and laboratory test results of each patient were not
included in the claim data; detailed characteristics of an-
terior uveitis (e.g., grade of inflammation, granulomatous
Fig. 3 Incidence of ankylosing spondylitis according to age, sex, and uveitis episode numbers
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or nongranulomatous), details of AS manifestation at on-
set, human leukocyte antigen B27 positivity, and levels of
C-reactive protein and acute-phase reactant at the onset
of uveitis or AS were not considered. This study would
have been more informative if these variables could have
been included in the regression model and if the analysis
had indicated which variables were valuable in predicting
subsequent AS occurrence in patients with uveitis, if any.
Inactivity and recurrence of uveitis were also estimated in-
directly by the type and schedule of prescribed medica-
tion. Although there are some intrinsic limitations of the
insurance claim data, the general trend of the association
between AS and recurrent uveitis was still obvious.
Conclusions
We evaluated the risk of subsequent AS development
after recurrent uveitis among Korean patients during a
10-year follow-up period. The incidence of AS increased
proportionally with the number of episodes of uveitis.
The estimated incidence of AS increased 7.4- and 17.7-
fold after the first and second episodes of uveitis, re-
spectively. This study provides a rationale for ancillary
workup for possible systemic associations in patients
with recurrent uveitis and emphasizes the importance of
multidisciplinary collaboration in the diagnosis and
management of AS.
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